A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
01 Mar 1995-Pharmaceutical Research (Kluwer Academic Publishers-Plenum Publishers)-Vol. 12, Iss: 3, pp 413-420
TL;DR: A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption.
Abstract: A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in
vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no
in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes. This classification scheme provides a basis for establishing in vitro-in vivo correlations and for estimating the absorption of drugs based on the fundamental dissolution and permeability properties of physiologic importance.
Citations
More filters
University of California, San Francisco1, Food and Drug Administration2, University of North Carolina at Chapel Hill3, Merck & Co.4, Abbott Laboratories5, Eli Lilly and Company6, Novartis7, German Cancer Research Center8, University of Western Ontario9, Pfizer10, University of Helsinki11, GlaxoSmithKline12, University of Tokyo13, University of Maryland, Baltimore14, Genentech15, University of Arizona16
TL;DR: Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions, as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Abstract: Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
2,879 citations
TL;DR: This review is intended to give a general background to the use of cyclodextrin as solubilizers as well as highlight kinetic and thermodynamic tools and parameters useful in the study of drug Solubilization bycyclodextrins.
1,674 citations
TL;DR: Of specific interest is the use of cyclodextrin-containing polymers to provide unique capabilities for the delivery of nucleic acids.
Abstract: Cyclodextrins are cyclic oligomers of glucose that can form water-soluble inclusion complexes with small molecules and portions of large compounds. These biocompatible, cyclic oligosaccharides do not elicit immune responses and have low toxicities in animals and humans. Cyclodextrins are used in pharmaceutical applications for numerous purposes, including improving the bioavailability of drugs. Current cyclodextrin-based therapeutics are described and possible future applications discussed. Cyclodextrin-containing polymers are reviewed and their use in drug delivery presented. Of specific interest is the use of cyclodextrin-containing polymers to provide unique capabilities for the delivery of nucleic acids.
1,650 citations
TL;DR: It is concluded that Caco-2 monolayers can be used to identify drugs with potential absorption problems, and possibly also to select drugs with optimal passive absorption characteristics from series of pharmacologically active molecules generated in drug discovery programs.
1,417 citations
TL;DR: The most common functional groups that are amenable to prodrug design are described, and examples of prodrugs that are either launched or are undergoing human trials are highlighted.
Abstract: Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.
1,412 citations
Cites background from "A Theoretical Basis for a Biopharma..."
...F a is largely controlled by the physicochemical parameters of the parent or prodrug, that is, its gastrointestinal permeability, solubility, dissolution rate and dose numbe...
[...]
References
More filters
TL;DR: The physical characteristics of chlorothiazide, rather than a saturable transport mechanism at the intestinal wall, may be responsible for the dose-dependent absorption observed for this drug.
79 citations
TL;DR: It is proposed that the major route for the oral absorption of terbutaline and antipyrine might be passive transcellular diffusion.
Abstract: The absorption mechanism(s) of terbutaline in the human jejunum was studied by using the intestinal perfusion instrument, Loc-I-Gut. The present study was divided into three parts. In Part I the absorption of 10 and 20 μM of both (+) and (-)-terbutaline enantiomers was studied. The influence of D-glucose (80 mM) on the net fluid transport across the intestinal wall and the effective intestinal permeability (Peff) of both (±)-terbutaline (10 μM) and antipyrine (0.5 mM) was investigated in Part II. The experimental design of Part III was similar to that in Part II, with the exception that the perfusion solution was hypotonic and had a D-glucose concentration of 80 mM. No statistical differences were found in the Peff between terbutaline enantiomers or their concentrations. D-glucose (80 mM) did neither affect net fluid transport nor the Peff of (±)-terbutaline and antipyrine in the human jejunum. In contrast, hypotonic D-glucose (80 mM) solution induced a net fluid absorption (p < 0.01). In parallel...
46 citations
TL;DR: The anatomical reserve length for the intestinal absorption of drugs is presented as the framework by which many physicochemical, physiological and dosage form factors are put into quantitative interrelationships.
Abstract: The anatomical reserve length for the intestinal absorption of drugs is presented as the framework by which many physicochemical, physiological and dosage form factors are put into quantitative interrelationships. The concept is a basic science approach to the optimization of oral drug formulations and provides a perspective in the selection of strategies and options within established boundaries. The framework, thus far described here, provides the base upon which refinements and other considerations can be added.What is not covered here are considerations of absorption windows, which we have defined as that part of the small intestine where absorption occurs for special mechanistic reasons. The windows include the pH-absorption window, distribution of aqueous pore pathways along the intestinal tract, specialized membrane transport mechanisms, membrane distribution of enzyme systems and differences in transit times in the intestinal tract. We have omitted this interesting topic from the reserve l...
44 citations
TL;DR: In this paper, a reasonably realistic physical model has been described for the simultaneous longitudinal spreading, fluid flow and absorption of drugs in solution under non-steady state conditions m the small intestinal tract Various input cases included first-order and zero-order stomach emptying and input from an infinite drug reservoir at constant infusion rate
43 citations
TL;DR: The binding to milk and casein was found to be not dependent on the concentration of drugs, and higher binding was observed at lower temperatures than at higher temperatures for both drugs examined.
33 citations